Chapter 45: Drugs for Angina Pectoris

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

What if I told you that the, uh, the oldest, most famous heart medication in the world?

Oh, nitroglycerin.

Yeah, exactly, nitroglycerin.

What if I told you a drug that has been saving lives for, I mean, over a century, doesn't actually work the way most people think it does?

It's, uh, it's actually a pretty huge misconception.

Right, because if you've ever pictured nitroglycerin, like forcibly wedging open a clogged, plaque -filled artery to save a patient from chest pain,

you know, you're not alone.

But today, we are completely dismantling that idea.

It's a fascinating misunderstanding and, uh, what makes nitroglycerin even more interesting is its origin.

I mean, this is the exact same volatile chemical used in dynamite.

Invented by Alfred Nobel, right?

Yep.

Back in the late 1800s, these factory workers who were making explosives, they actually noticed their chronic chest pain mysteriously vanished while they were on the clock.

That is just wild.

It really is.

That bizarre workplace observation literally birthed a cornerstone of modern cardiology.

I love that.

Well, welcome to the Deep Dive.

Consider this your very own, uh, one -on -one clinical tutoring session.

We are so glad you're sitting down with us today.

Absolutely.

Our mission today is to take you straight through Chapter 45 of Lane's Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants.

And that chapter focuses entirely on the drugs for angina pictoris.

Right.

And we aren't just going to read a list of medications at you.

We are going to explore the mechanics.

So we'll start with the underlying mechanical failures in the heart, move through the specific drug classes, and finally,

uh, build out the clinical decision -making frameworks you'll actually use.

Yeah, because by the time we wrap up, you'll be fully prepared to make safe, patient -centered decisions.

Exactly.

And that's really the key, right?

Patient -centered decisions.

Because memorization without comprehension is, well, it's dangerous in clinical practice.

Oh, totally.

If you don't know the why behind a treatment, you won't recognize when a standard guideline might actually harm the specific patient sitting in front of you.

Like why does a certain drug work beautifully for one patient,

but, you know, cause a fatal drop in blood pressure for another?

Exactly.

Understanding that underlying logic is what transforms you into a truly confident clinician.

Okay, so let's unpack this.

Before we even think about prescribing a pill or a patch, we have to understand the mechanical failure we are treating.

The text defines angina pictoris as sudden pain beneath the sternum, often radiating to the left shoulder, the left arm, and jaw.

But that pain is really just the fire alarm.

Yeah, the actual fire is a supply and demand mismatch.

And to treat it, you have to know which of the two main types of angina your patient actually has.

So there's chronic stable angina, which happens during exertion, and then variant angina, which is also known as a basospastic or Prince metal angina.

And that distinction is basically the bedrock of your entire treatment plan, isn't it?

It really is.

To visualize this,

just imagine a scale balancing oxygen supply on one side and oxygen demand on the other.

In a perfectly healthy heart, that scale is always balanced.

When you exercise, your heart beats faster, it pumps harder, so it's a demand for oxygen naturally rises.

Makes sense.

And to meet that demand, your coronary arterioles automatically dilate.

They just open up, increasing blood flow and delivering more oxygen to the heart muscle.

But in a heart with coronary artery disease, or CAD, the mechanics are completely altered.

This is where I usually picture a car engine with a partially blocked fuel line.

Oh, that's a good analogy.

Yeah, so if you're just idling at a stoplight, which is like the patient sitting quietly at rest, the engine hums along perfectly fine.

It can pull just enough fuel through that blocked line to keep running.

But the moment you jump on the highway and slam the gas pedal, demanding a surge of power, the engine sputters and struggles.

The blocked fuel line is a great start, but let's refine it clinically just a bit.

It's more like a fuel line that has entirely lost its physical ability to expand when you hit the gas.

Oh, I see.

Because there is so much plaque buildup in those arteries, the arterioles downstream are already fully dilated at rest, just to pull enough blood past the blockage to keep the resting heart alive.

Wait, so they are maxed out before the patient even stands up?

Exactly.

Because those arterioles are already wide open at rest, when the patient exerts themselves, say they're, I don't know, walking up a flight of stairs, there is absolutely no physiological room left to increase blood flow.

The demand for oxygen spikes, but the supply is physically capped by the plaque.

And that mismatch is what causes the ischemic pain of chronic stable angina.

So understanding this really dictates our entire therapeutic strategy.

Completely.

Since we cannot simply give them more oxygen because the arteries are physically occluded, our only medical option is to decrease the heart's oxygen demand.

Yes, we have to reduce the workload.

But if a patient has variant angina, the strategy totally flips, doesn't it?

It has to flip.

Variant angina isn't caused by fixed, stubborn plaque.

It's caused by sudden coronary artery spasms that just clamp down and restrict blood flow.

And that can happen at any time, right?

Even while the patient is asleep.

Exactly, even fast asleep.

Because the pain is caused by a sudden severe drop in oxygen supply, our therapeutic goal here is to increase that supply by stopping or preventing the spasm.

Okay, so now that we know our primary mission for stable angina is reducing the heart's workload,

the oxygen demand, let's go back to that dynamite derivative.

Ah, the organic nitrates.

Yes, nitroglycerin is the prototype here.

And this brings me back to my massive misconception, because for years I just assumed you plug a nitro into your tongue and it rushes to those plaque -filled coronary arteries and it forcibly opens them to push more blood in.

It is an incredibly common assumption, but it is entirely backward.

Really?

Nitroglycerin does not dilate atherosclerotic coronary arteries.

In fact, if you inject it directly into the coronary arteries during an antigen attack, it doesn't even relieve the pain.

Wait, really?

It doesn't do anything?

Nope.

The magic of nitroglycerin happens out in the periphery of the body, like far away from the heart itself.

Okay, walk us through that.

So when nitroglycerin enters the body, it converts to its active form, nitric oxide.

And this conversion requires the presence of sulfhydryl groups.

Sulfhydryl groups, got it.

Right.

Once converted, the nitric oxide activates an enzyme called groinally cyclous, which causes vascular smooth muscle to relax.

And here is where the crucial pharmacodynamic distinction comes in, right?

Because at normal therapeutic doses, this relaxation happens primarily in the veins, not the arteries.

Precisely.

By dilating the veins, you are essentially creating a massive holding area for blood in the arms and legs.

It's like a traffic control measure.

Exactly.

You're holding the traffic back out in the periphery so the blood pools in the venous system.

And because the blood is pooling, less of it returns to the heart.

When venous return drops, the heart's ventricles don't fill with as much blood.

This drop in ventricular filling significantly reduces the tension on the heart wall, which we call preload.

Okay, so by reducing preload, the heart is pumping a smaller volume of blood.

It doesn't have to work as hard, which drastically lowers its oxygen demand.

It's brilliant.

We aren't forcing the clogged pipes open.

We're just asking the pump to do less work.

That's a perfect way to put it.

Now, I know for varian angina, it does work by relaxing those coronary spasms to increase oxygen supply.

But for the standard stable angina patient, it is all about reducing preload via the veins.

That's right.

And to achieve that, we really have to talk about how the drug is administered because the pharmacokinetics are very specific.

Right.

Nitroglycerin is highly lipid soluble, meaning it crosses cellular membranes incredibly easily.

That's why we give it subliminally, like under the tongue or through a transdermal patch on the skin.

I was wondering why we don't just give them a daily pill to swallow.

Ah, because of something called the first pass effect.

Think of the liver as a highly aggressive security guard.

If you swallow a nitroglycerin pill, it goes straight to the liver,

and the hepatic enzymes destroy almost all of the drug before it ever reaches the systemic bloodstream.

Wow, almost all of it.

Yeah.

And even when it does get into the blood via a patch or under the tongue, its plasma half -life is incredibly fast, only about five to seven minutes.

That rapid action is exactly what you want to stop an acute attack in its tracks, but we do have to warn you about the adverse effects.

Because it's such a potent vasodilator, your patients are definitely going to experience headaches.

Oh yeah, severe headaches at first.

But you can reassure them that this usually fades over the first few weeks of therapy.

They might also experience orthostatic hypotension, you know, getting dizzy when they stand up.

But what is the most dangerous adverse effect we need to watch for?

Reflex tachycardia.

Right.

Because nitroglycerin causes blood pooling and drops the blood pressure, the body's baroreceptors sense that drop and they basically panic.

They trigger the sympathetic nervous system to speed the heart up to compensate.

But a racing heart requires more oxygen.

Exactly.

That is the exact opposite of what we want when we're trying to reduce the heart's workload.

We also absolutely must highlight the drug interactions here.

Nitroglycerin is strictly contraindicated with phosphatase S3 type V inhibitors, like sildenafil.

Yes, very important.

If a patient mixes them, the vasodilation compounds on itself, causing a catastrophic, life -threatening drop in blood pressure.

You also have to manage patient education really carefully regarding tolerance.

The text spends a lot of time on this.

Tolerance to nitroglycerin develops incredibly fast, sometimes within a single day.

Wow, that fast.

Yeah.

Remember those self -hydro groups we mentioned earlier?

The ones needed to convert the drug into nitric oxide.

Right.

The leading theory is that continuous use of nitroglycerin actually depletes those groups.

And without them, the drug just stops working.

So how do we fix that?

Well, to prevent this, patients absolutely must have an 8 to 12 hour nitrate -free interval every single day.

Usually we just have them remove their patch overnight while they sleep.

Okay, so nitroglycerin is an amazing tool, but we just established that it can trigger reflex tachycardia.

So if the body panics and speeds the heart up, how do we stop the heart from racing and ruining the therapy?

Enter our next class of drugs, the beta blockers.

Yes.

For chronic stable angina, these are your first line baseline drugs.

But to be crystal clear, they are not used for variant angina.

Right.

For a patient with stable angina, beta blockers like proprinolol or the beta 1 selective drug metaprolol are essential.

They work by blocking the beta 1 receptors directly in the heart muscle.

And when you block those receptors, you decrease the heart rate and you decrease the force of contractility.

Exactly.

Both of those actions directly lower the heart's oxygen demand.

The clinical dosing goal is actually very specific.

We want to reduce their resting heart rate to between 50 and 60 beats per minute and cap their exertional heart rate at about 100 beats per minute.

Okay, I want to push back on a concept here because it sounds a little counterintuitive.

The text says beta blockers actually increase the heart's oxygen supply by increasing time and diastole.

Yeah.

So by forcing the heart to take longer, slower breaks between beats, it actually gets more time to feed itself.

It sounds strange, but it's pure physiological mechanics.

Think about how a heart beats.

During systole, when the heart forcefully contracts to push blood out to the body, it is physically squeezing its own coronary artery shut.

Oh, I see.

Yeah.

Blood can't flow through a clamped tube.

So coronary artery perfusion, the blood flow that feeds the heart muscle itself, happens almost entirely during diastole when the heart muscle relaxes and those arteries open up.

Oh, wow.

So if the heart is racing, that relaxation phase is cut extremely short and the heart literally starves itself of oxygen because it never stops squeezing.

Exactly.

By slowing the heart down with a beta blocker, you prolong that crucial relaxation phase, giving the blood more time to flow into the myocardial vessels.

That's a brilliant dual benefit.

You decrease the demand by slowing the workload and you slightly increase the supply by extending diastole.

Right.

And circling back to our previous problem, they are the perfect partner for nitrates because they completely block that dangerous reflex tachycardia.

But they aren't without risks.

I mean, if we suppress the heart too much, we can cause severe bradycardia, AV block, and even trigger heart failure.

Yes.

And we have to be incredibly careful when looking at a patient's medical history.

Like, if your patient has asthma, you have a major problem.

A huge problem.

Non -selective beta blockers will also block beta -2 receptors in the lungs, which can trigger severe bronchoconstriction.

Right.

So if an asthma patient must have one, you have to use a beta -1 selective agent like Metaprol.

Correct.

They can also mask the early warning signs of hypoglycemia, like a racing pulse, so you have to tread very carefully with diabetic patients.

Which naturally brings up a major clinical obstacle.

Say you have a patient with severe asthma and a beta blocker is just too risky.

We need a drug that drops the workload without touching the lungs.

Where do we turn?

We move to the calcium channel blockers, or CCBs.

The text highlights three main CCBs for angina.

Nifedipine, verapamil, and diltiasm.

Their primary mechanism of action is blocking calcium channels in the vascular smooth muscle, specifically in the arterioles.

And when you block calcium, the smooth muscle relaxes, causing arterial or dilation.

Which reduces peripheral resistance, what we call afterload.

And we need a good way to visualize afterload.

Because if preload is the volume of blood stretching the heart before it pumps.

Afterload is the resistance the heart has to push against to get the blood out.

Exactly.

Imagine trying to push open a heavy door against a really strong wind.

That wind is the afterload.

I like that.

By dilating those arterioles with a CCB, you are basically taking the wind away.

The door opens easily, and the heart's oxygen demand drops significantly.

And unlike beta blockers, CCBs can be used for variant angina because they effectively relax the spasms in the coronary arteries.

Yes, that's a huge distinction, but we have to clearly separate the CCBs into two distinct groups because they behave very differently.

Okay, let's break that down.

You have the dihydropyridines, like nifedipine.

Nifedipine only dilates those arterioles out in the body.

Then you have the non -dihydropyridines, which are verapamil and diltiasm.

These drugs dilate the arterioles, but they also travel to the heart and directly suppress the cardiac pacemaker and contractility.

Which leads to a really crucial clinical distinction.

If both of these types lower blood pressure by dilating blood vessels, which one do you think is going to cause the worst reflex tachycardia?

Well, it has to be nifedipine, right?

Absolutely.

Because nifedipine only dilates the blood vessels and does absolutely nothing to the heart directly, the sudden drop in blood pressure triggers the baroreceptor reflex and the heart races to compensate.

Oh, right.

Whereas verapamil and diltiasm also lower blood pressure, but because they have built -in heart -slowing effects, they naturally suppress that reflex tachycardia from happening.

Exactly.

But that built -in heart suppression comes with a massive warning label.

If verapamil or diltiasm already slow the heart down, you must use extreme caution if you ever combine them with the beta blocker.

Oh, absolutely.

You run the risk of dangerous additive cardio suppression that can just stop the heart entirely.

A very critical safety alert.

Now, up until this point, every drug we've discussed is a hemodynamic drug.

You know, they alter blood pressure, vascular tone, or heart rate.

But what if we could protect the heart without messing with hemodynamics at all?

That brings us to ranolazine.

This was actually the first new class of anti -anginal agents approved in over 25 years, and it works completely differently.

Right.

It does not reduce heart rate.

It does not drop blood pressure.

Instead, it actually changes the way the heart uses energy.

It appears to improve the myocardium's energy efficiency by reducing the accumulation of sodium and calcium inside the individual myocardial cells.

So it allows the heart to do the same amount of work while burning less oxygen?

Exactly.

It sounds like an absolute magic bullet.

I mean, improving energy without dropping blood pressure?

Why isn't this the ultimate first choice for every single patient?

Well, because the real -world benefits are actually quite modest.

Interestingly, clinical trials showed it is notably less effective in women than in men, though we aren't entirely sure why.

But the main reason it isn't a magic bullet is its severe side -effect profile and intense drug interactions.

Rolazine carries a serious risk for QT prolongation.

Okay, let's translate that for a second.

QT prolongation means the electrical reset phase of the heartbeat is taking too long.

If it takes too long, you risk a short circuit in the heart's electrical system, which can lead to a fatal ventricular rhythm called torsades de pointe.

Exactly.

And the risk of that fatal rhythm skyrockets if the renolazine levels in the blood get too high.

This drug is heavily metabolized by a liver enzyme called CYP3A4.

Ah, CYP3A4.

Yeah.

Think of CYP3A4 as a specific processing plant in the liver.

If a patient takes renolazine along with something that inhibits that processing plant like grapefruit juice or macrolide antibiotics like erythromycin or HIV protease inhibitors like ritonavir, the liver just stops processing the renolazine.

And the drug levels spike to toxic levels.

Yes, and the patient could go into a fatal rhythm.

And we have to highlight a very specific clinical rule here, what we can call the amlodipine exception.

Oh, this is important.

If your patient's angina is in control and you need to combine renolazine with a calcium channel blocker, you must use amlodipine.

Why is that?

Because most other CCBs, like our friends verapamil and diltiazum, actually inhibit that CYP3A4 processing plant.

Combining them with renolazine will cause that toxic, fatal accumulation.

Amlodipine is the safe exception because it doesn't block the enzyme.

That is such a key takeaway.

Okay, so we have all the pharmacological puzzle pieces on the table.

We understand the nitrates, the beta blockers, the CCBs, and renolazine.

Now let's assemble them into the actual clinical guidelines used in practice.

We don't just guess which drug to use, there is a highly structured logical flow plan.

And the text highlights a major paradigm shift in how we approach this.

Treatment of stable angina has two very distinct objectives, and they are ranked by importance.

Okay, what's objective number one?

Objective number one is preventing myocardial infarction and death.

Objective number two is the reduction of ischemic pain.

So the golden rule is this, if two drugs relieve pain equally well, you must choose the one that also prevents death.

That makes perfect sense.

And here is the twist.

To meet that first objective, preventing death.

We aren't even using the anti -anginal drugs we just spent the last 10 minutes talking about.

Wait, really?

Yeah.

To prevent a heart attack, the guidelines mandate prescribing antiplatelet drugs like aspirin or clopidogrel to prevent blood clots from forming on the plaque.

They mandate statins to lower cholesterol, but more importantly, statins stabilize the lipid core of the plaque so it doesn't rupture and cause a fatal clot.

And finally, they mandate ACE inhibitors like Ramapril.

Why an ACE inhibitor for angina?

The clinical data is just undeniable.

The Hopi trial showed that Ramapril drastically reduced the incidence of stroke, MI and cardiovascular death, especially in patients who also have diabetes.

It protects the vascular endothelium.

Oh, wow.

So every stable angina patient should be evaluated for this protective trifecta, aspirin, a statin and an ACE inhibitor.

Once we know the patient is protected from dying, we can move to objective two, improving their quality of life by reducing the pain.

Instead of just citing the textbook flow plan, let's walk through it as a clinical journey.

Your patient is sitting in the exam room.

Base therapy starts with sublingual nitroglycerin to carry in their pocket for acute attacks, plus a daily beta blocker to prevent the attacks from happening.

And we choose the beta blocker first because it's the preferred baseline agent that actually decreases mortality, especially if they have a history of a prior MI.

Step two,

what if they come back a month later and the beta blocker isn't enough?

Or what if they have severe asthma and can't take it?

Then you add or substitute a long -acting calcium channel blocker.

But remember our earlier warning.

If you are adding a CCB to a beta blocker, you want to use a dihydropyridine like nifedipipine or imlotipine to avoid crushing the heart's conduction system with dual suppression.

Step three,

if the CCB still isn't controlling the pain, you add a long -acting nitrate.

Right.

And if all of this maximal medical therapy fails,

then and only then do you consider sending them for surgical revascularization like a CIBG or placing a stent.

But as you know, the art of medicine is dealing with comorbidities.

You have to match the exact drug mechanism to the patient's unique physiological landscape.

If your angina patient has asthma, you avoid beta blockers and lean on a CCB.

If the patient has moderate to severe heart failure, you might carefully use a beta blocker or amlotipine, but you never use verapamil or diltiasm because their cardio -suppressed effects could push that failing heart over the edge into shock.

And let's not forget the simple rules for variant angina.

Because it's caused by spasms, the steps are slightly different.

Right.

Start with a CCB or a long -acting nitrate to relax the spasm.

If one fails, combine them.

If the combination fails, go to surgery.

But the golden rule for variant angina is no beta blockers.

None.

They do absolutely nothing to relax coronary vasospasm and might actually make it worse.

Finally, we have to counsel the patient on lifestyle risk factors.

Smoking cessation is non -negotiable, and they need 30 to 60 minutes of aerobic exercise a few times a week to condition the heart.

Which brings us to a really fascinating paradox hidden near the end of the chapter's risk reduction section.

Oh, I love this part.

We naturally assume that fiercely controlling every single risk factor is always going to yield the best results.

For example, in diabetic patients, we know for a fact that maintaining tight, aggressive glycemic control heavily reduces microvascular complications,

like damage to the eyes and the kidneys.

But here is the provocative thought we want to leave you with today.

The text points out that there is surprisingly little evidence that tight glycemic control actually reduces cardiovascular mortality risk in these patients.

Yeah, it's wild.

In fact, if you push their blood sugar too low with aggressive, tight control, it might actually be harmful to the heart and increase their risk of an adverse event.

It is a profound reminder for you as you step into practice.

We rely on algorithms, medication tables, and flow charts because they represent the very best scientific evidence we currently have.

But human physiology is, well, it's endlessly complex, and sometimes it behaves in ways that are entirely counterintuitive.

You always have to treat the whole patient sitting in front of you, not just a set of numbers on a chart.

Absolutely.

Well, we hope this deep dive into Chapter 45 has helped clarify these mechanisms for you.

Understanding the why behind preload, afterload, and CYP3A4 enzymes is what will make you a truly exceptional, adaptable provider.

So true.

On behalf of all of us here at the Deep Dive and the Last Minute Lecture Team, thank you so much for joining us for this tutoring session.

Keep asking the hard questions, and we wish you the absolute best of luck in your clinical practice.